Bristol-Myers Squibb and Duke Translational Medicine Institute form strategic relationship

Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE:BMY) and Duke Translational Medicine Institute (DTMI) announced the formation of a strategic relationship to broaden interactions between the two organizations. The relationship builds on a decade of collaboration in cardiology, endocrinology, and oncology, and will extend into other therapeutic areas at all stages of development, fostering increased exchange between DTMI researchers, and Bristol-Myers Squibb scientists and project teams.

For the first project, DTMI translational researchers led by Drs. Paul Noble and John Sundy will work with Bristol-Myers Squibb scientists on the clinical development of BMS-986202, an orally available lysophosphatidic acid 1 (LPA1) receptor antagonist under investigation to treat idiopathic pulmonary fibrosis (IPF). The cross-organizational team will co-develop and co-implement the protocol for a Phase II study that is expected to begin in late 2012, and will undertake biomarker validation studies. IPF is a chronic, progressive form of lung disease characterized by fibrosis, or scarring of lung tissue, with limited treatment options.

Future projects could include working together to accelerate promising investigational drugs into proof-of-concept studies, improving enrollment in clinical trials, and developing disease educational programs.

"More and more, scientific innovation in drug development is happening at the crossroad of different disciplines; so, it is important to nurture relationships at these crossroads," said Elliott Sigal, M.D., Ph.D., executive vice president, chief scientific officer and president R&D, Bristol-Myers Squibb. "Both Bristol-Myers Squibb and DTMI have talented teams of world-class scientists and with our shared commitment to innovative solutions, our hope is that this partnership will allow the organizations to collaborate on projects involving all phases of research, development and disease education."

"We plan for this to provide an excellent example of how we can fundamentally improve the effectiveness and transparency of academic and industry partnerships and relationships," said Robert M Califf, MD, Vice Chancellor for Clinical and Translational Research and Director of the Duke Translational Medicine Institute. "Our work with Bristol-Myers Squibb takes advantage of the scientific and clinical expertise within both organizations and creates opportunities by removing barriers to collaboration, employing rigorous statistical analysis, and encouraging the groups to learn from each other, while we keep our focus on patients and improving health." Bristol-Myers Squibb and DTMI have established a joint steering committee of functional leaders and scientists that will forge the partnership, identify the points of intersection, and prioritize projects.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

About Duke Translational Medicine Institute
Duke University is a leading university dedicated to promoting global health through advanced biomedical research, graduate-level education in the life sciences and health professions, and delivery of patient care. Duke Translational Medicine Institute employs approximately 1300 scientists, project leaders, statisticians, biomedical informaticists, and educators. DTMI is dedicated to catalyzing translation across the continuum of scientific discovery, clinical research, care delivery, and global health.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

Consuming milk at breakfast lowers blood glucose t…

A change in breakfast routine may provide benefits for the management of type 2 diabetes, according to a new study published in the Journal of Dairy Science. H. Douglas G...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Bristol-Myers Squibb - Pfizer Alliance ACROPOLIS™ …

The Bristol-Myers Squibb-Pfizer Alliance will present 15 Eliquis® (apixaban) posters at the ESC Congress 2018 held in Munich, Germany, August 25-29, 2018. Nine of the pos...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

SOLAR-1 trial of Novartis investigational alpha-sp…

Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint s...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...